Table 3 Correlation analyses between inflammatory and AD CSF biomarkers by diagnostic category
From: Glial activation and inflammation along the Alzheimer’s disease continuum
All symptomatic subjects (SCD, MCI, AD dementia) (n = 85) | |||||
Variable | CSF sTREM2 | CSF YKL-40 | CSF MCP-1 | CSF Fractalkine | CSF Clusterin |
CSF Aβ42 | n.s. | n.s. | n.s. | n.s. | n.s. |
CSF T-tau | .318, p < .01 | .589, p < .001 | .276, p < .05 | .507, p < .001 | .400, p < .001 |
CSF P-tau | .289, p < .01 | .444, p < .001 | n.s. | .368, p < .001 | .290, p < .01 |
SCD (n = 18) | |||||
Variable | CSF sTREM2 | CSF YKL-40 | CSF MCP-1 | CSF Fractalkine | CSF Clusterin |
CSF Aβ42 | n.s. | n.s. | n.s. | n.s. | .568, p < .05 |
CSF T-tau | .629, p < .01 | .730, p < .001 | n.s. | .616, p < .01 | n.s. |
CSF P-tau | .655, p < .01 | .679, p < .01 | n.s. | .536, p < .05 | n.s. |
MCI (n = 40) | |||||
Variable | CSF sTREM2 | CSF YKL-40 | CSF MCP-1 | CSF Fractalkine | CSF Clusterin |
CSF Aβ42 | n.s. | n.s. | n.s. | n.s. | n.s. |
CSF T-tau | n.s. | .409, p < .01 | n.s. | .479, p < .01 | .330, p < .05 |
CSF P-tau | .335, p < .05 | .347, p < .05 | n.s. | .375, p < .05 | .364, p < .05 |
AD dementia (n = 29) | |||||
Variable | CSF sTREM2 | CSF YKL-40 | CSF MCP-1 | CSF Fractalkine | CSF Clusterin |
CSF Aβ42 | n.s. | n.s. | n.s. | n.s. | n.s. |
CSF T-tau | n.s. | .660, p < .001 | n.s. | .550, p < .01 | .415, p < .05 |
CSF P-tau | n.s. | .439, p < .05 | n.s. | n.s. | n.s. |